Chest
Original ResearchLung CancerReassessment of Declines in Pulmonary Function ≥ 1 Year After Stereotactic Body Radiotherapy
Section snippets
Patients
We retrospectively identified consecutive patients with localized primary lung cancer or solitary metastatic lung tumors treated with SRBT at Ofuna Chuo Hospital between February 2005 and September 2010. A total of 292 patients with 313 lung tumors were identified. Of these 292 patients, 19 had two metachronous lesions and one had three metachronous lesions; all lesions were treated with SBRT at different times. All patients received pretreatment PFTs. In November 2010, to assess long-term
Results
Among the 292 patients treated with SBRT, 184 patients were alive at November 2010 when posttreatment pulmonary function testing was initiated (Fig 1). Among these 184 patients, 142 underwent follow-up PFT at ≥ 1 year after SBRT. The other patients had either concluded follow-up prior to initiation of posttreatment PFT (November 2010), had died within 1 year after SBRT, were lost to follow-up or followed up only by telephone contact, or had experienced local recurrence or a second lung cancer.
Declines in Pulmonary Function Parameters Following SBRT
In this study, the most important implication is that declines in FEV1 and FVC after SBRT, even for patients with GOLD III-IV, were small after a median posttreatment duration of 21 months (range, 12.0-74.8 months). The median ΔFEV1/preFEV1 and ΔFVC/preFVC in patients with GOLD III-IV were 7.4% and 3.6%, respectively. The median, 25th percentile, and 75th percentile in ΔFEV1/preFEV1 and ΔFVC/preFVC in patients with GOLD III-IV were similar to those in patients with NPF or GOLD I-II (Fig 3).
Acknowledgments
Author contributions: Dr Takeda is guarantor of the manuscript and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Takeda: contributed to designing the search strategy; data abstraction, analysis, and interpretation; drafting the manuscript; revising the manuscript critically for important intellectual content; approving the final version of the manuscript; and served as principal author.
Dr Enomoto: contributed to data abstraction, analysis, and
References (24)
- et al.
Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma
Cancer Treat Rev
(2008) - et al.
Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors
Int J Radiat Oncol Biol Phys
(2005) - et al.
Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy
Chest
(2012) - et al.
Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy
Int J Radiat Oncol Biol Phys
(2009) - et al.
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer
Chest
(2003) - et al.
Pulmonary function testing after stereotactic body radiotherapy to the lung
Int J Radiat Oncol Biol Phys
(2012) - et al.
Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients
J Thorac Oncol
(2009) - et al.
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition)
Chest
(2007) - et al.
Determinants of perioperative morbidity and mortality after pneumonectomy
Ann Thorac Surg
(1989) - et al.
Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review
Int J Radiat Oncol Biol Phys
(2012)
Body mass index and the risk of COPD
Chest
The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?
Curr Oncol Rep
Cited by (34)
Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial
2023, International Journal of Radiation Oncology Biology PhysicsManagement of Oligometastatic Colorectal Cancer
2023, Surgical Clinics of North AmericaPulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung
2017, Radiotherapy and OncologyCitation Excerpt :Investigation of pulmonary function changes after lung tumor SABR has primarily emphasized the small significant or non-significant PFT changes from baseline that occur during follow-up. The safety and low observed toxicity following lung tumor SABR in patients with poor pulmonary reserve is necessary to provide a viable alternative treatment for non-operable candidates with early-stage NSCLC [31]. Quality of life after lung tumor SABR has been reported as stable for the majority of patients [37].
Funding/Support: The authors have reported to CHEST that no funding was received for this study.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.